Want to see HIMS full AI Analyst Report?
HIMS Stock Chart & Stats
$25.05
-$0.61(-2.20%)
At close: 4:00 PM EST
$25.05
-$0.61(-2.20%)
Day’s Range― - ―
52-Week Range$13.74 - $70.43
Previous CloseN/A
Volume4.28M
Average Volume (3M)15.98M
Market Cap
$6.50B
Enterprise Value$5.12K
Total Cash (Recent Filing)$750.88M
Total Debt (Recent Filing)$1.13B
Price to Earnings (P/E)―
Beta2.57
Next Earnings
Aug 10, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding223,080,080
10 Day Avg. Volume14,448,064
30 Day Avg. Volume15,981,831
Financial Highlights & Ratios
PEG Ratio-33.04
Price to Book (P/B)13.50
Price to Sales (P/S)3.11
P/FCF Ratio98.76
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$30.46Price Target Upside21.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.13
Revenue Forecast (FY)$2.93B
Bulls Say, Bears Say
Bulls Say
Large Recurring Subscriber Base And EngagementA ~2.6M subscriber base with predictable monthly additions and strong initial engagement creates durable recurring revenue and higher customer lifetime value. High app usage and multiple provider touches in month one increase retention odds and reduce acquisition dependence over multiple quarters.
Strong Operating Cash Flow And Positive Free Cash FlowConsistent positive operating and free cash flow provides lasting financial flexibility to fund product expansion, international M&A, and supply‑chain investments without immediate equity raises. Reliable cash conversion supports reinvestment and lowers short‑term liquidity risk over the next several quarters.
Rapid Branded GLP‑1 Adoption And Accelerating International ScaleQuick uptake of branded GLP‑1s demonstrates product-market fit in a high‑growth clinical category and expands addressable market. Simultaneous ~10x international revenue growth and M&A (Eucalyptus) create scale benefits, diversified revenue streams, and longer‑term unit economics improvements.
Bears Say
Markedly Higher LeverageA sharp rise in leverage materially increases refinancing and covenant risk and reduces capital flexibility. Higher interest and fixed‑charge burdens constrain investment optionality and magnify earnings volatility if growth or margins slow over the next several quarters.
Gross-margin Compression And GAAP VolatilityScaling lower‑margin specialties (weight‑loss, labs, international) and one‑time supply chain write‑downs suggest structurally lower near‑term gross margins. This makes operating leverage more fragile and GAAP results volatile, complicating multi‑quarter profit predictability and planning.
New Convertible Debt And Potential DilutionSignificant convertible issuance alters future capital structure and can dilute shareholders if converted. While it funds international expansion and ops, the notes add contingent claims and complexity to refinancing strategy, elevating structural dilution and governance considerations over coming quarters.
Hims & Hers Health News
HIMS FAQ
What was Hims & Hers Health, Inc.’s price range in the past 12 months?
Hims & Hers Health, Inc. lowest stock price was $13.74 and its highest was $70.43 in the past 12 months.
What is Hims & Hers Health, Inc.’s market cap?
Hims & Hers Health, Inc.’s market cap is $6.50B.
When is Hims & Hers Health, Inc.’s upcoming earnings report date?
Hims & Hers Health, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 14 days.
How were Hims & Hers Health, Inc.’s earnings last quarter?
Hims & Hers Health, Inc. released its earnings results on May 11, 2026. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of $0.025 by -$0.425.
Is Hims & Hers Health, Inc. overvalued?
According to Wall Street analysts Hims & Hers Health, Inc.’s price is currently Undervalued.
Does Hims & Hers Health, Inc. pay dividends?
Hims & Hers Health, Inc. does not currently pay dividends.
What is Hims & Hers Health, Inc.’s EPS estimate?
Hims & Hers Health, Inc.’s EPS estimate is -0.05.
How many shares outstanding does Hims & Hers Health, Inc. have?
Hims & Hers Health, Inc. has 223,080,080 shares outstanding.
What happened to Hims & Hers Health, Inc.’s price movement after its last earnings report?
Hims & Hers Health, Inc. reported an EPS of -$0.4 in its last earnings report, missing expectations of $0.025. Following the earnings report the stock price went up 3.077%.
Which hedge fund is a major shareholder of Hims & Hers Health, Inc.?
Currently, no hedge funds are holding shares in HIMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hims & Hers Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$30.46 (21.59% Upside)
$30.46 (21.59% Upside)
Blogger Sentiment
Bullish
HIMS Sentiment 82%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 3.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $342.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 87%
Bearish news 13%
Bearish news 13%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-50.99%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
154.24%
Trailing 12-Months
Company Description
Hims & Hers Health, Inc.
Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific non-prescription offerings span categories such as: Wellness: encompassing items like vitamin C, melatonin, biotin, and collagen protein supplements. Skincare: including products such as moisturizers, serums, and face washes. Sexual Health: providing essentials like condoms, climax delay sprays and wipes, vibrators, and lubricants. Hair Care: offering specialized shampoos, conditioners, scalp scrubs, and topical treatments like minoxidil. Beyond direct sales, Hims & Hers also distributes health and wellness products via wholesale partnerships. The company's headquarters are located in San Francisco, California.
HIMS Company Deck
HIMS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of near-term headwinds tied to a deliberate strategic pivot (one-time restructuring charges, gross-margin pressure, GAAP loss and short-term volatility) alongside several strong growth signals: raised full-year revenue guide, rapid adoption of branded GLP-1 products (125k+ Wegovy shipments in six weeks and on track for >100k monthly subscribers), international revenue growth (~10x to $78M), positive operating cash flow ($89M) and deep investments in AI, labs and verticalized supply chain. Management expects accelerating EBITDA in H2 as monthly cohorts compound and efficiencies emerge. Given the substantial operational and commercial progress and the forward-looking guidance offsetting temporary accounting and margin noise, the positive operational momentum and upgraded outlook outweigh the short-term financial disruptions.View all HIMS earnings summariesHIMS Revenue Breakdown
96.60% Online
3.40% Wholesale
HIMS Stock 12 Month Forecast
Average Price Target
$30.46
▲(21.59% Upside)
Technical Analysis
Ownership Overview
5.21% Insiders
14.77% Mutual Funds
0.43% Other Institutional Investors
58.73% Public Companies and Individual Investors